Home > Press > Company Profile for Techulon Inc
Abstract:
Techulon is a life sciences company with a core capability in the development, characterization and synthesis of novel gene delivery techniques for cell-based therapeutics. Our proprietary nanoparticle delivery platform, Glycofect, is a polymer-based reagent that delivers DNA and RNA into cells with lower cell toxicity and high protein expression. The company is focused on delivery for therapeutically relevant cells such as primary cells. Applications for this new technology range from research on cellular metabolism to advanced forms of cancer treatment. First indications include neurodegenerative diseases and glioma.
Company: Techulon Inc
Headquarters Address: 2200 Kraft Drive, Ste 2475
Blacksburg, VA 24060
Main Telephone: 540-443-9254
Website: www.techulon.com
Type of Organization: Private
Industry: Biotechnology
Key Executives: CEO: Frank Akers
####
For more information, please click here
Contacts:
Investor Relations
Contact:
Brett Malone
Copyright © Business Wire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||